BIOVERIC Pharmaceuticals, Inc. today announced the launch of its redesigned website at bioveric.com, timed to the company's second anniversary. The new site gives partners, investors and prospective collaborators a clearer view of BIOVERIC's neurology-led pipeline, its patient-centric approach to development, and the team behind it.
Two years of BIOVERIC: six programs advanced. More than ten patents filed.
Six programs have advanced from feasibility into development across neurology, cardiovascular and antiviral care. Each was selected through a two-year evaluation of patient need, commercial potential and intellectual property.
Alongside that development work, the company has filed more than ten patent applications, spanning PCT international applications and U.S. provisional and U.S. non-provisional applications.
The redesigned site reflects that progress, showing development stage program by program across BIOVERIC's therapeutic areas.
For partnering or investment inquiries, contact investors@biovericpharma.com.
BIOVERIC's programs are investigational product candidates. They have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency, and their safety and effectiveness have not been established.
← All news